Erratum: Network analysis of transcriptional regulation in response to intramuscular interferon-Β-1a multiple sclerosis treatment (The Pharmacogenomics Journal (2012) 12 (134-146) DOI: 10.1038/tpj.2010.77);Network analysis of transcriptional regulation in response to intramuscular interferon-β-1a multiple sclerosis treatment

Pharmacogenomics Journal

Volumn 12, Issue 2, 2012, Pages 134-146

  Hecker, M ^a,b   Goertsches, R H ^b   Fatum, C ^b   Koczan, D ^b   Thiesen, H J ^b   Guthke, R ^a   Zettl, U K ^b  

^a HANS KNÖLL INSTITUTE   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

DNA microarray; interferon beta; multiple sclerosis; network analysis

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; ASTHENIA; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESPONSE; FEMALE; FEVER; FLU LIKE SYNDROME; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INTERACTION; GENE REGULATORY NETWORK; HEADACHE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; MYALGIA; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

EID: 84455207166     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2011.12     Document Type: Erratum

References (62)

1. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65: 239-248.
2. Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372: 1502-1517.
3. Bradl M, Lassmann H. Progressive multiple sclerosis. Semin Immunopathol 2009; 31: 455-465.
4. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747. (Pubitemid 40563183)
5. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294. (Pubitemid 26100751)
6. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898-904.
7. Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol 2007; 254: 67-77. (Pubitemid 46295070)
8. Stark GR. How cells respond to interferons revisited: from early history to current complexity. Cytokine Growth Factor Rev 2007; 18: 419-423. (Pubitemid 47302834)
9. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A et al. Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis. J Neuroimmunol 2005; 158: 195-203. (Pubitemid 39626087)
10. Santos R, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Zivadinov R, Justinger T et al. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol 2006; 176: 125-133. (Pubitemid 44080329)
11. Weinstock-Guttman B, Bhasi K, Badgett D, Tamaño-Blanco M, Minhas M, Feichter J et al. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 2008; 205: 113-125.
12. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171: 2694-2702. (Pubitemid 37025583)
13. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-189. (Pubitemid 36875298)
14. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R et al. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40-47. (Pubitemid 40967774)
15. Goertsches RH, Hecker M, Zettl UK. Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks. J Neurol 2008; 255(Suppl 6): 48-57.
16. Comabella M, Martin R. Genomics in multiple sclerosis - current state and future directions. J Neuroimmunol 2007; 187: 1-8. (Pubitemid 47001533)
17. Hesse D, Krakauer M, Lund H, Søndergaard HB, Limborg SJ, Soelberg Sørensen P et al. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis? Eur J Neurol 2010; e-pub ahead of print 15 June 2010; doi:10.1111/j.1468-1331.2010.03116.x.
18. Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE et al. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 2009; 16: 1291-1298.
19. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 2007; 258: 52-59. (Pubitemid 46874477)
20. Fernald GH, Knott S, Pachner A, Caillier SJ, Narayan K, Oksenberg JR et al. Genome-wide network analysis reveals the global properties of IFN-beta immediate transcriptional effects in humans. J Immunol 2007; 178: 5076-5085. (Pubitemid 46595291)
21. Hecker M, Lambeck S, Toepfer S, van Someren E, Guthke R. Gene regulatory network inference: data integration in dynamic models - a review. Biosystems 2009; 96: 86-103.
22. Cho KH, Choo SM, Jung SH, Kim JR, Choi HS, Kim J. Reverse engineering of gene regulatory networks. IET Syst Biol 2007; 1: 149-163. (Pubitemid 46831209)
23. Ross AP. Tolerability, adherence, and patient outcomes. Neurology 2008; 71(24 Suppl 3): S21-S23.
24. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.
25. Ferrari F, Bortoluzzi S, Coppe A, Sirota A, Safran M, Shmoish M et al. Novel definition files for human GeneChips based on GeneAnnot. BMC Bioinformatics 2007; 8: 446.
26. Hecker M, Goertsches RH, Engelmann R, Thiesen HJ, Guthke R. Integrative modeling of transcriptional regulation in response to antirheumatic therapy. BMC Bioinformatics 2009; 10: 262.
27. Yang IV, Chen E, Hasseman JP, Liang W, Frank BC, Wang S et al. Within the fold: assessing differential expression measures and reproducibility in microarray assays. Genome Biol 2002; 3: research0062.
28. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007; 23: 257-258. (Pubitemid 46189622)
29. Mahony S, Benos PV. STAMP: a web tool for exploring DNA-binding motif similarities. Nucleic Acids Res 2007; 35(Web Server issue): W253-W258.
30. Efron B, Hastie T, Johnstone I, Tibshirani R. Least angle regression. Ann Statist 2004; 32: 407-499. (Pubitemid 41250302)
31. Killcoyne S, Carter GW, Smith J, Boyle J. Cytoscape: a community-based framework for network modeling. Methods Mol Biol 2009; 563: 219-239.
32. Clauset A, Shalizi CR, Newman MEJ. Power-law distributions in empirical data. SIAM Review 2009; 51: 661-703.
33. Melchjorsen J, Kristiansen H, Christiansen R, Rintahaka J, Matikainen S, Paludan SR et al. Differential Regulation of the OASL and OAS1 Genes in Response to Viral Infections. J Interferon Cytokine Res 2009; 29: 199-208.
34. Ishibashi K, Kuwahara M, Gu Y, Tanaka Y, Marumo F, Sasaki S. Cloning and functional expression of a new aquaporin (AQP9) abundantly expressed in the peripheral leukocytes permeable to water and urea, but not to glycerol. Biochem Biophys Res Commun 1998; 244: 268-274. (Pubitemid 28419937)
35. Kraft S, Kinet JP. New developments in FcepsilonRI regulation, function and inhibition. Nat Rev Immunol 2007; 7: 365-378. (Pubitemid 46674486)
36. Giorelli M, Livrea P, Defazio G, Iacovelli L, Capobianco L, Picascia A et al. Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, beta-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytes. Cell Signal 2002; 14: 673-678. (Pubitemid 34520462)
37. Hamilton JA. CSF-1 signal transduction. J Leukoc Biol 1997; 62: 145-155. (Pubitemid 27380786)
38. Huang W-X, Huang MP, Gomes MA, Hillert J. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 2000; 55: 928-934.
39. Wandinger KP, Lünemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361: 2036-2043. (Pubitemid 36695046)
40. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004; 14: 359-372. (Pubitemid 43231798)
41. Tanaka N, Kawakami T, Taniguchi T. Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. Mol Cell Biol 1993; 13: 4531-4538. (Pubitemid 23220360)
42. Mizugishi K, Aruga J, Nakata K, Mikoshiba K. Molecular properties of Zic proteins as transcriptional regulators and their relationship to GLI proteins. J Biol Chem 2001; 276: 2180-2188. (Pubitemid 32109701)
43. Stürzebecher S, Maibauer R, Heuner A, Beckmann K, Aufdembrinke B. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res 1999; 19: 1257-1264.
44. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 2000; 20: 857-866.
45. Stürzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126(Part 6): 1419-1429. (Pubitemid 36644386)
46. Annibali V, Di Giovanni S, Cannoni S, Giugni E, Bomprezzi R, Mattei C et al. Gene expression profiles reveal homeostatic dynamics during interferon-beta therapy in multiple sclerosis. Autoimmunity 2007; 40: 16-22. (Pubitemid 46332418)
47. Goertsches RH, Hecker M, Koczan D, Serrano-Fernandez P, Moeller S, Thiesen HJ et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010; 11: 147-161.
48. Kraus J, Bauer R, Chatzimanolis N, Engelhardt B, Tofighi J, Bregenzer T et al. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol 2004; 251: 464-472. (Pubitemid 38501307)
49. Floris S, Ruuls SR, Wierinckx A, van der Pol SM, Döpp E, van der Meide PH et al. Interferon-beta directly influences monocyte infiltration into the central nervous system. J Neuroimmunol 2002; 127: 69-79. (Pubitemid 34603576)
50. Calvete JJ. On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor. Proc Soc Exp Biol Med 1995; 208: 346-360.
51. Stalker TJ, Wu J, Morgans A, Traxler EA, Wang L, Chatterjee MS et al. Endothelial cell specific adhesion molecule (ESAM) localizes to platelet-platelet contacts and regulates thrombus formation in vivo. J Thromb Haemost 2009; 7: 1886-1896.
52. Ishida T, Kundu RK, Yang E, Hirata K, Ho YD, Quertermous T. Targeted disruption of endothelial cell-selective adhesion molecule inhibits angiogenic processes in vitro and in vivo. J Biol Chem 2003; 278: 34598-34604. (Pubitemid 37553309)
53. Weber C, Fraemohs L, Dejana E. The role of junctional adhesion molecules in vascular inflammation. Nat Rev Immunol 2007; 7: 467-477. (Pubitemid 46834851)
54. Montalban X, Durán I, Río J, Sáez-Torres I, Tintoré M, Martínez-Cáceres EM. Can we predict flu-like symptoms in patients with multiple sclerosis treated with interferon-beta? J Neurol 2000; 247: 259-262. (Pubitemid 30223961)
55. Nie D, Tang K, Diglio C, Honn KV. Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 2000; 95: 2304-2311. (Pubitemid 30167729)
56. Pidgeon GP, Tang K, Cai YL, Piasentin E, Honn KV. Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha(v)beta(3) and alpha(v)beta(5) integrin expression. Cancer Res 2003; 63: 4258-4267. (Pubitemid 36917955)
57. Shelhamer JH, Marom Z, Kaliner M, Sun F, Bach MK. The effects of arachinoids and leukotrienes on the release of mucus from human airways. Chest 1982; 81: 36S-37S. (Pubitemid 12040260)
58. Emerson MR, LeVine SM. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res 2004; 1021: 140-145. (Pubitemid 39158666)
59. Wang X, Newkirk RF, Carre W, Ghose P, Igobudia B, Townsel JG et al. Regulation of ANKRD9 expression by lipid metabolic perturbations. BMB Rep 2009; 42: 568-573.
60. Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S et al. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res 2009; 69: 8133-8140.
61. Tremlett H, Oger J. Hepatic injury, liver monitoring and the betainterferons for multiple sclerosis. J Neurol 2004; 251: 1297-1303.
62. Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain 2009; 132(Part 12): 3353-3365.